Investor type Private Equity Firm


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 20
Average round size
The average size of a deal this fund participated in
Portfolio companies 18
Rounds per year 2.86
Lead investments 6
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 3
Key employees 5

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Pharmaceutical

This Fund+ works on 18 percentage points less the average amount of lead investments comparing to the other organizations. The real fund results show that this VC is 13 percentage points more often commits exit comparing to other companies. The fund is generally included in less than 2 deals every year. The usual things for fund are deals in the range of 10 - 50 millions dollars. The top amount of exits for fund were in 2014. The high activity for fund was in 2017. Despite it in 2019 the fund had an activity.

We also calculated 5 valuable employees in our database.

The typical case for the fund is to invest in rounds with 6-7 participants. Despite the Fund+, startups are often financed by Caixa Capital Risc, Shire, SFPI-FPIM. The meaningful sponsors for the fund in investment in the same round are S.R.I.W., V-Bio Ventures, SFPI-FPIM. In the next rounds fund is usually obtained by curative ventures, V-Bio Ventures, Shinsei Corporate Investment Limited.

The fund has specific favorite in a number of founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. Besides, a startup needs to be aged 2-3 years to get the investment from the fund. Among the most successful fund investment fields, there are Pharmaceutical, Health Care. Among the various public portfolio startups of the fund, we may underline Minoryx Therapeutics, ITeos Therapeutics, Promethera Biosciences

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Fund+:
Typical Co-investors
Fund+ is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Fund+:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
China Fortune Holdings Limited China, Hong Kong, New Territories
CrowdStrike Falcon Fund California, Sunnyvale, United States
Deciphera Pharmaceuticals Massachusetts, United States, Waltham
Ewing Irrigation & Landscape Supply Arizona, Phoenix, United States
Ford Foundation New York, New York, United States
FoxKiser District of Columbia, United States, Washington
Generation Growth Capital Chicago, Illinois, United States
Gera Venture Capital Brazil, Rio de Janeiro, Rio De Janeiro
Guangzhou Qin Yue China, Guangdong, Guangzhou
ICM Asset Management Bayern, Germany, Munich
IncuVest Central, Central Region, Singapore
Launch LAB Greensboro, North Carolina, United States
Mobai Capital China, Guangdong, Guangzhou
redfin -
San-in Godo Bank Japan, Matsue, Shimane Prefecture
Seoul Global Startup Center -
SYBO Games Copenhagen, Denmark, Hovedstaden
Version One Ventures British Columbia, Canada, Vancouver
Weicheng Juncheng Investment China, Fujian, Xiamen
Wisdom Sports Group China, Hong Kong, Hong Kong Island

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation


Health Care
Life Science
$70M03 May 2022 Munich, Bavaria, Germany

TargED Biopharmaceuticals

Health Care
$46M19 Feb 2022 Utrecht, Utrecht, The Netherlands

EyeD Pharma

$53M24 Dec 2021 Liege, Liège, Belgium

Novadip Biosciences

Health Care
$22M28 Oct 2021 Belgium, Walloon Brabant, Belgium

Egle Therapeutics

Health Care
$47M22 Oct 2021 Paris, Ile-de-France, France

Cardior Pharmaceuticals

$75M25 Aug 2021 Hanover, Lower Saxony, Germany

ExeVir Bio

Health Care
Life Science
$49M28 Jul 2020 Ghent, East Flanders, Belgium

Indigo Diabetes

Health Care
Medical Device
$44M27 Jul 2020 Belgium, East Flanders

Ona Therapeutics

Health Care
Life Science
$35M16 Jun 2020 Catalonia
Cardior Raises €64M in Series B Funding

– Cardior Pharmaceuticals from Hanover develops non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases.
– The company closed a €64m ($76m) Series B financing round.
– The round was led by Inkef Capital, supported by fellow new investors Fund+, Sunstone, Hadean Ventures and Coparion with participation from existing investors including LSP, BioMedPartners, Bristol Myers Squibb and High-Tech Gründerfonds.
– The new investment will be used for the late-stage clinical development of its lead program and the expansion of its earlier-stage pipeline.

ExeVir Announces Close of US$50 million / EUR42 million Series A Financing

– ExeVir closed its Series A financing raising a total of EUR 42 million / US$50 million.
– The financing was led by Fund++ with VIB, UCB Ventures, SFPI-FPIM, V-Bio Ventures and new investors SRIW, Noshaq, Vives IUF, SambrInvest, as well as several Belgian family offices.
– ExeVir will use the financing to commence the global phase 1b/2 clinical trial of lead compound XVR011 that is scheduled to start shortly.
– The company also plans to develop a VHH72-Fc sub-cutaneous formulation for Covid-19 in parallel and accelerate development of its pipeline beyond Covid-19 in infectious diseases.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Fund+?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: